Certain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers. Changes in lipids, adiponectin, leptin, plasminogen activator inhibitor 1 (PAI-1) and the adhesion molecules E-selectin and P-selectin were also assessed.
Methods
This was a single-centre, randomized, double-blinded, placebo-controlled study that used a two-sequence, two-period cross-over design. A total of 19 HIV-negative males were recruited to the study and randomized 1:1 to receive either 2 weeks of TDF (300 mg once daily) followed by 2 weeks of placebo or placebo initially followed by tenofovir. Clamps were performed at baseline, after 2 weeks and after 4 weeks.
Results
All three clamps were completed by 16 participants. During the euglycaemic clamp, there were no significant changes in insulin sensitivity after 2 weeks of TDF administration compared with placebo or baseline. There was a significant reduction in the mean total cholesterol (9.4%) and low-density lipoprotein (LDL; 8.1%) cholesterol following 2 weeks of TDF compared with placebo. Levels of adiponectin, leptin, PAI-1, P-selectin and E-selectin were not significantly altered.
Conclusions
TDF use for 2 weeks does not affect insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp in HIV-negative male volunteers. TDF use resulted in modest, but statistically significant, reductions in total and LDL cholesterol.
References
1.
Antiretroviral Therapy Cohort Collaboration.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet2008; 372: 293–299.
2.
LundgrenJ., ReissP., WormS.Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: the D:A:D study.Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 44LB.
3.
De WitS., SabinC.A., WeberR.Incidence and risk factors for new-onset diabetes in HIV-infected patients the data collection on adverse events of anti-HIV drugs (D:A:D) study.Diabetes Care2008; 31: 1224–1229.
4.
GrinspoonS., CarrA.Cardiovascular risk and body-fat abnormalities in HIV-infected adults.N Engl J Med2005; 352: 48–62.
5.
DeFronzoR.A., TobinJ.D., AndresR.Glucose clamp technique: a method for quantifying insulin secretion and resistance.Am J Physiol1979; 237: E214–E23.
LeeG.A., RaoM., MulliganK.Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.AIDS2007; 21: 2183–2190.
8.
NoorM.A., FlintO.P., MaaJ-F, ParkerR.A.Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.AIDS2006; 20: 1813–1821.
9.
NoorM.A., LoJ.C., MulliganK.Metabolic effects of indinavir in healthy HIV-seronegative men.AIDS2001; 15: F11–F18.
10.
NoorM.A., ParkerR.A., O'MaraE.The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.AIDS2004; 18: 2137–2144.
11.
NoorM.A., SeneviratneT., AweekaF.T.Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.AIDS2002; 16: F1–F8.
12.
BlumerR.M.E., vanVonderenM.G.A., SutinenJ.Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting antiretroviral therapy.AIDS2008; 22: 227–236.
13.
FleischmanA., JohnsenS., SystromD.M.Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.Am J Physiol Endocrinol Metab2007; 292: E1666–E1673.
14.
MurataH., HruzP.W., MuecklerM.The mechanism of insulin resistance caused by HIV protease inhibitor therapy.J Biol Chem2000; 275: 20251–20254.
15.
LeeG.A., SeneviratneT., NoorM.A.The metabolic effects of lopinavir/ritonavir in HIV negative men.AIDS2004; 18: 641–649.
BirkusG., HitchcockM.J.M., CihlarT.Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.Antimicrob Agents Chemother2002; 46: 716–723.
18.
JacksonA., PatelN., LoG., GazzardB., MoyleG.Effects of atazanavir or saquinavir QD with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal; a randomised open-label study.Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Poster 818.
19.
RandellP., JacksonA., TaylorJ., MandaliaS., MoyleG.The effects of fosamprenavir or lopinavir with ritonavir, lamivudine and tenofovir, as initial treatment for HIV-1 infection, on insulin sensitivity.11th European AIDS Conference. 24–27 October 2007, Madrid, Spain. Poster LBP92/1.
20.
GallantJ.E., StaszewskiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients.JAMA2004; 292: 191–201.
21.
ArribasJ.R., PozniakA.L., GallantJ.E.Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients.J Acquir Immune Defic Syndr2008; 47: 74–78.
22.
MoyleG.J., SabinC., CartledgeJ.A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.AIDS2006; 20: 2043–2050.
23.
AnanworanichJ., NueschR., CôtéH.C.. Changes in metabolic toxicity after switching from stavudine/ didanosine to tenofovir/lamivudine – a Staccato trial substudy.J Antimicrob Chemother2008; 61: 1340–1343.
24.
FisherM., MoyleG.J., ShahmaneshM.A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir DF/emtricitabine in efavirenz-treated HIV-1 infected individuals.J Acquir Immune Defic Syndr2009; 51: 562–568.
25.
TungsiripatM., KitchD., GlesbyM.A pilot study to determine the effect on dyslipidemia of the addition of tenofovir to stable background ART in HIV-infected subjects: results from the A5206 Study Team.Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 714.
26.
YamauchiT., KamonJ., WakiH.The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.Nat Med2001; 7: 941–946.
27.
KubotaN., TerauchiY., YamauchiT.Disruption of adiponectin causes insulin resistance and neointimal formation.J Biol Chem2002; 277: 25863–25866.
28.
WeltC.K., ChanJ.L., BullenJ.Recombinant human leptin in women with hypothalamic amenorrhea.N Engl J Med2004; 351: 987–997.
29.
ChanJ.L., MatareseG., ShettyG.K.Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans.Proc Natl Acad Sci U S A2006; 103: 8481–8486.
30.
AhimaR.S., PrabakaranD., MantzorosC.Role of leptin in the neuroendocrine response to fasting.Nature1996; 382: 250–252.
31.
JanV., CerveraP., MaachiM.Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients.Antivir Ther2004; 9: 555–564.
KoppelK., BrattG., SchulmanS., BylundH., SandströmE.Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.J Acquir Immune Defic Syndr2002; 29: 441–449.
34.
SipsasN.V., SfikakisP.P., TouloumiG., PantazisN., ChoremiH., KordossisT.Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients.AIDS Patient Care STDS2003; 17: 147–153.
35.
MuH., ChaiH., LinP.H., YaoQ., ChenC.Current update on HIV-associated vascular disease and endothelial dysfunction.World J Surg2007; 31: 632–643.
